Everest Organics has informed the exchanges that they will be making the API for the generic version of Merck's anti Covid-19 drug molnupiravir. The company has joined hands with Divi's Labs for making this API. Here we speak with Srikakarlapudi Sirisha, CEO of Everest Organics, and Vishal Manchanda of Nirmal Bang Institutional Equities, who explain how big is the opportunity for molnupiravir from an API perspective.

#CNBCTV18 #BusinessNews #ShareMarketToday #Nifty #Sensex #SrikakarlapudiSirisha #VishalManchanda #EverestOrganics #MolnupiravirAPI

CNBC-TV18 is India's No.1 Business medium and the undisputed leader in business news. The channel's benchmark coverage extends from corporate news, financial markets coverage, expert perspective on investing and management to industry verticals and beyond. CNBC-TV18 has been constantly innovating with new genres of programming that helps make business more relevant to different constituencies across India. India's most able business audience consumes CNBC-TV18 for their information & investing needs. This audience is highly diversified at one level comprising of key groups such as business leaders, professionals, retail investors, brokers and traders, intermediaries, self-employed professionals, High Net Worth individuals, students and even homemakers but shares a distinct commonality in terms of their spirit of enterprise.

For latest news and updates visit our Website: https://bit.ly/2YbpXBM
Subscribe to our Channel: https://www.youtube.com/user/CNBCTV18
Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News

Everest Organics Develops Molnupiravir API, Here We Discuss This Opp | Halftime Report | CNBC-TV18

Merck has separately entered into voluntary licensing agreements with at least eight Indian generic drugmakers for molnupiravir, to turn the country into a manufacturing hub for the drug.

COVID-19: Everest Organics starts making ingredient for Merck’s molnupiravir drug

The Indian bulk drugs manufacturer joins Divi’s Laboratories Ltd as an API maker for Merck’s experimental oral drug. Merck has separately entered into voluntary licensing agreements with at least eight Indian generic drugmakers for molnupiravir, with an aim to turn the country into a manufacturing h…

India’s Everest Organics starts making ingredient for Merck’s COVID-19 pill

‘Molnupiravir’ is an API that reduces the risk of hospitalization and death by around 50% for patients with mild or moderate cases of Covid.

Everest Organics ends 15% higher on development of Molnupiravir, a new API to treat Covid-19

Everest Organics standalone net profit rises 124.31% in the December 2020 quarter

BRIEF-Everest Organics Declared Interim Dividend Of 50 Paisa Per Share

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags